Shire Announces Award Recipients for 2013 US ADHD Scholarship Program

    Shire Announces Award Recipients for 2013 US ADHD Scholarship Program

Scholarship Program designed for individuals with
Attention-Deficit/Hyperactivity Disorder (ADHD) going on to higher education

PR Newswire

PHILADELPHIA, July 18, 2013

PHILADELPHIA, July 18, 2013 /PRNewswire/ --

Shire, a global specialty biopharmaceutical company, has named the recipients
of its 2013 US ADHD Scholarship Program. The program is for individuals in the
United States diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD)
who are pursuing higher education at a college, vocational school, or
technical school. Fifty award recipients have been selected from [2030]
applicants across the United States. The recipients were selected on the basis
of an essay explaining how ADHD has impacted their lives, letters of
recommendation, community service, and volunteer and extracurricular

In 2011, Shire introduced the ADHD Scholarship Program and awarded 25
scholarships. Due to the tremendous response, Shire doubled the number of
scholarships to 50 in 2012. Shire will offer 50 scholarships in 2013. The
scholarship program is part of Shire's patient-centric approach that offers
support to patients with ADHD and their caregivers.

The Shire ADHD Scholarship includes a $2,000 monetary award and a prepaid year
of ADHD coaching services. The coaching services are intended to assist the
recipients in their pursuit of higher education and are provided by the Edge
Foundation. For more information on the program, please visit

The 2013 winners are: Bates, Meagan, Delaware; Bowman, Christian, Maryland;
Butler, Enamarie, Maryland; Carray, Mariah, California; Copeland, Lewis,
Virginia; Craft, Joshua, Mississippi; Erwin, Emily, Nebraska; French, Gabriel,
Kentucky; Gilliam, Zachary, Texas; Hansen, Mallory, New Jersey; Jirsa,
Jessica, Missouri; Kriz, Connor, Kentucky; Kuebbing, Joseph, Kentucky; Larkin,
Zachary, California; Lewis, Austin, Georgia; Luberda, Joshua, Virginia; Lukas,
Christopher, Mississippi; Martin, Jacqueline, Alabama; Meek, Lauren,
Washington, DC; Moses, Kristen, Illinois; Peterson, Ryan, New Hampshire; Ruiz,
Jessica, California; Sanders, Jordan, Florida; Scalisi, David, California;
Shelton, Stuart, Tennessee; Silva, Ryan; Louisiana; Stickney, Haley, Florida;
VandeLune, Christopher, Illinois; Wesler, Katherine, Alabama.

The remainder of the 2013 recipients requested that their names not be

"I am proud to recognize the award recipients of the ADHD Scholarship
Program," said Scott Applebaum, Senior Vice President of Shire's Neuroscience
Business Unit. "The program received thousands of applications from
individuals with ADHD who are pursuing higher education. The Shire team is
thrilled to be able to help these individuals with both tuition assistance and
ADHD coaching services."

Award recipients will be offered ADHD coaching from the Edge Foundation, which
includes weekly sessions with trained ADHD coaches. The students set weekly
goals and action plans to meet those goals and have e-mail and phone support
from their coaches to help keep them on track.

"This program is in its third year and has now gone international to include
students in Canada. Shire has consistently supported post-secondary students
with ADHD, and has encouraged the growth of this program, which is now double
in size to where we were when it started," said Robert Tudisco, Executive
Director of the Edge Foundation. "We applaud Shire's continued and increased
support for students with ADHD."

The Edge Foundation is a Seattle-based nonprofit organization that offers
support for students with ADHD. The Edge Foundation's primary mission is to
provide access to qualified, professional coaches for students with ADHD as
part of their multimodal treatment program.


Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal,
Internal Medicine and Regenerative Medicine and we are developing treatments
for symptomatic conditions treated by specialist physicians in other targeted
therapeutic areas.

For further information please contact:




SOURCE Shire Pharmaceuticals Group
Press spacebar to pause and continue. Press esc to stop.